Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

 

Latest Presentation

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

09 Nov '2021
Olema Oncology to Present at Two Upcoming Investor Conferences
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that management

Events & Presentations

SEC Filings

Filing date Description Form

Statement of changes in beneficial ownership of securities

 4

Report of unscheduled material events or corporate event

 8-K

Quarterly report which provides a continuing view of a company's financial position

 10-Q